ScienceAs drug giants grow cautious, can Chinese biotech firms still cash in on licensing deals?

Record cross-border deals helped some formerly loss-making Chinese biotech companies turn profitable in the first half of the year. Analysts said partnerships with global drugmakers had become the main funding route for cash-strapped firms advancing new-drug discovery, clinical development and regulatory approval, overtaking IPOs and pre-IPO fundraising as multinationals signal tighter deal budgets.

Chinese biotechlicensing dealspharmaceutical industry

SSouth China Morning Post★★☆☆☆2026-08-25 05:00Original